Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Abbott hits record...

    Abbott hits record high as blood sugar monitoring device- FreeStyle Libre 2 fuels profit

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-19T15:02:35+05:30  |  Updated On 16 Aug 2021 10:55 AM IST

    Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.


    Shares rose 4% to a record high of $86.59, adding to the about 15% gain since the start of the year.


    Abbott is betting on the device, FreeStyle Libre, and is working on newer versions to cushion slowing growth in some of its older products.


    Also Read: Abbott to increase production of lower-cost glucose monitors as diabetes soars


    ls without having to prick their fingers, is used by more than 1.5 million people worldwide.


    FreeStyle Libre 2, the next-generation device, which is already approved in Europe, is now under U.S. regulatory review.


    To expand its reach, Abbott plans to ramp up manufacturing capacity for FreeStyle Libre by three to five times in the next few years, Reuters reported on Tuesday.


    When asked on the conference call what that increased capacity could mean, Chief Executive Miles White said he sees potential for Libre to bring in annual sales of $5 billion "in a reasonable time".


    Libre's sales are expected to reach $1.5 billion this year, the company has said.


    Abbott is also focusing on another growth driver, MitraClip. Sales of the device used for heart valve repair jumped 26.7% to $169 million in the quarter.


    Momentum continues for Abbott's key growth drivers and "we don't believe it is slowing down any time soon", BMO Capital Markets analyst Joanne Wuensch wrote in a client note.


    Sales of FreeStyle Libre rose 63.9% on a reported basis to $433 million in the second quarter.


    Total sales at the diabetes unit jumped 28.2% and helped Abbott's medical devices division report a 6.4% rise in revenue to $3.08 billion.


    Also Read: AstraZeneca Farxiga fails to win USFDA approval for Type-1 diabetes


    Abbott raised its 2019 forecast for adjusted earnings from continuing operations to $3.21 to $3.27 per share, from its prior forecast of $3.15 to $3.25 per share.


    The company's net earnings rose 37% to $1 billion in the second quarter ended June 30.


    Excluding items, Abbott earned 82 cents per share, ahead of the average analyst estimate of 80 cents, according to IBES data from Refinitiv.


    Net sales rose 2.7% to $7.98 billion, but missed estimates of $8 billion.


    (By Saumya Joseph, Manas Mishra and Julie Steenhuysen)

    AbbottAbbott healthcareAbbott Laboratoriesabbott medical devicesBMOdevice fueldiabetesFreeStyle LibreIBESJoanne WuenschMitraClippharmapharma companypharma newsprofit beatRefinitiv
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok